Research shows serum FABP4 is associated with liver damage and kidney complications in thalassemia, indicating potential health risks.
A significant difference was seen between serum FABP4 and bilirubin and AST/ALT ratio, showing a connection between serum FABP4 and liver injury and kidney complications. Consequently, while further studies are essential for a comprehensive exploration of this hypothesis, serum FABP4 may have a potential role in chronic diseases in thalassemia patients.
No takes yet. Share an insight, caveat, or question.
Belbesi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: